Understanding Checkpoint Inhibitors in Cancer Therapy, Mechanisms of Action, Resistance and Future Challenges
Understanding Checkpoint Inhibitors in Cancer Therapy, Mechanisms of Action, Resistance and Future Challenges
Review Data
Q: Is the topic relevant to the journal area of interest? Is it contemporary and interesting for
researchers?
A: Excellent
Abstract & Keywords
Q: Are all required components included in the abstract? Are the keywords appropriately chosen?
A: Very good; In the last sentence of the Abstract, “program death” must be replaced with “programmed death” both times.
Goal
Q: Is the goal explicitly stated in the Introduction? Is its formulation clear and unambiguous?
A: Very good
Structure
Q: Is the paper's structure coherent? Is it in coherence with the goal of the paper?
A: Very good
Tools and Methods
Q: Are methods the author uses adequate and well used?
A: Good
Discussion & Conclusion
Q: Is it related to the results presented before? Do you consider them as coherent?
A: Good
Comments:
The Conclusion provides an apt summary of the current status of the field of immune checkpoint inhibitors research and development and the future directions in the field.
Literature
Q: Does the author utilize relevant literature?
A: Good
Author's knowledge
Q: What is the level of the author’s knowledge? Does the author utilize all recent contributions relevant to the topic?
A: Good
Length
Q: Is the length of the paper adequate to the significance of the topic? Do you suggest shortening the paper without losing its value?
A: Good
Figures & Tables
Q: Does the author use them suitably? Are legend and notations clear?
A: Very good
Writing style
Q: Is it clear and understandable?
A: Good
Further comments on the paper
Comments: This article offers a detailed and insightful review of the pathways involved in anticancer immune response, evasion and suppression of the immune system by cancer, mechanisms of action and success of immune checkpoint inhibitors (ICI), particularly programmed death-1 and programmed death-ligand inhibitors as well as mechanisms that result in resistance of cancer cells to ICI and the future challenges in this field.
Q: Would you recommend this manuscript for further publication?
A: Yes - Suitable to be published
If you have any questions and clarifications you can write to the journal.
Thanks,
Science Repository Team
Science Repository This email is restricted to the intended user. |
Science Repository - Support |
Author Info
Harman Saman Shahab Uddin Syed Raza Raj Shrimali Kakil Rasul
Corresponding Author
Harman SamanConsultant in Respiratory and Internal Medicine and Cancer Researcher, Hamad Medical Corporation-Qatar, Doha, Qatar
Article Info
Article Type
Review ArticlePublication history
Received: Mon 24, Aug 2020Accepted: Fri 25, Sep 2020
Published: Wed 30, Sep 2020
Copyright
© 2023 Harman Saman. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.DOI: 10.31487/j.COR.2020.09.08